Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597441 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation
A Phase 1 study, sponsored by Sumitomo Pharma Switzerland.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00597441 is a Phase 1 study that was terminated before completion, run by Sumitomo Pharma Switzerland. The registered enrollment target is 6 participants.
The verdict
NCT00597441, a Phase 1 study, was terminated before completion, sponsored by Sumitomo Pharma Switzerland.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of this trial is to assess the toxicity of thymus transplantation following unrelated umbilical cord blood transplantation. Emphasis will be placed on adverse events that are not typically associated with umbilical cord blood transplantation. Also, to determine whether engraftment of a third party thymus allograft is feasible in patients who have undergone unrelated umbilical cord blood transplantation.
Interventions
- BIOLOGICAL Thymic Transplantation for Recipients of UCB transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00597441
The ClinicalTrials.gov registry entry for NCT00597441 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thymic Transplantation for Recipients of UCB transplant is the first listed.
NCT00597441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00597441 about?
NCT00597441 is a clinical study titled "Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation". The objective of this trial is to assess the toxicity of thymus transplantation following unrelated umbilical cord blood transplantation. Emphasis will be placed on adverse events that are not typically associated with umbilical cord blood transplantation. Also, to determine whether engraftment of a...
What is the current status of trial NCT00597441?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2005-11. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00597441?
The interventions under investigation include: Thymic Transplantation for Recipients of UCB transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00597441?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.